Roche Holding AG
SIX:ROG
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| CH |
|
Roche Holding AG
SIX:ROG
|
207B CHF |
9%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
681.8B USD |
14%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-2%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
366.7B USD |
12%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
27%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
181.7B CHF |
13%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161B GBP |
7%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
191.6B USD |
16%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-51%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
131.8B USD |
4%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.1B EUR |
10%
|
Roche Holding AG
Glance View
Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Roche Holding AG's most recent financial statements, the company has ROA of 8.6%.
You don't have any saved screeners yet